BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kadiyala D, Roer DA, Perazella MA. Nephrogenic Systemic Fibrosis Associated With Gadoversetamide Exposure: Treatment With Sodium Thiosulfate. American Journal of Kidney Diseases 2009;53:133-7. [DOI: 10.1053/j.ajkd.2008.09.016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Bernstein EJ, Schmidt-lauber C, Kay J. Nephrogenic systemic fibrosis: A systemic fibrosing disease resulting from gadolinium exposure. Best Practice & Research Clinical Rheumatology 2012;26:489-503. [DOI: 10.1016/j.berh.2012.07.008] [Cited by in Crossref: 61] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
2 Zou Z, Zhang HL, Roditi GH, Leiner T, Kucharczyk W, Prince MR. Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases. JACC Cardiovasc Imaging 2011;4:1206-16. [PMID: 22093272 DOI: 10.1016/j.jcmg.2011.08.013] [Cited by in Crossref: 70] [Cited by in F6Publishing: 57] [Article Influence: 7.0] [Reference Citation Analysis]
3 Galperin TA, Cronin AJ, Leslie KS. Cutaneous manifestations of ESRD. Clin J Am Soc Nephrol. 2014;9:201-218. [PMID: 24115194 DOI: 10.2215/cjn.05900513] [Cited by in Crossref: 32] [Cited by in F6Publishing: 11] [Article Influence: 3.6] [Reference Citation Analysis]
4 Kielstein JT, Schiffer M. [Nephrogenic systemic fibrosis: a rare disease with grave consequences]. Internist (Berl) 2010;51:39-44. [PMID: 20033388 DOI: 10.1007/s00108-009-2408-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
5 Bardin T, Richette P. Nephrogenic systemic fibrosis. Current Opinion in Rheumatology 2010;22:54-8. [DOI: 10.1097/bor.0b013e328333bf3d] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
6 Zou Z, Ma L. Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases. Indian J Dermatol. 2011;56:65-73. [PMID: 21572796 DOI: 10.4103/0019-5154.77556] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
7 Weller A, Barber JL, Olsen ØE. Gadolinium and nephrogenic systemic fibrosis: an update. Pediatr Nephrol 2014;29:1927-37. [DOI: 10.1007/s00467-013-2636-z] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 5.7] [Reference Citation Analysis]
8 Gauden AJ, Phal PM, Drummond KJ. MRI safety: nephrogenic systemic fibrosis and other risks. J Clin Neurosci 2010;17:1097-104. [PMID: 20542435 DOI: 10.1016/j.jocn.2010.01.016] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
9 Attari H, Cao Y, Elmholdt TR, Zhao Y, Prince MR. A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis. Radiology. 2019;292:376-386. [PMID: 31264946 DOI: 10.1148/radiol.2019182916] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 14.3] [Reference Citation Analysis]
10 Karcaaltincaba M, Oguz B, Haliloglu M. Current status of contrast-induced nephropathy and nephrogenic systemic fibrosis in children. Pediatr Radiol 2009;39 Suppl 3:382-4. [PMID: 19440757 DOI: 10.1007/s00247-009-1236-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
11 Prince MR, Zhang HL, Roditi GH, Leiner T, Kucharczyk W. Risk factors for NSF: a literature review. J Magn Reson Imaging. 2009;30:1298-1308. [PMID: 19937930 DOI: 10.1002/jmri.21973] [Cited by in Crossref: 94] [Cited by in F6Publishing: 77] [Article Influence: 7.8] [Reference Citation Analysis]
12 Abu-Alfa AK. Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Adv Chronic Kidney Dis. 2011;18:188-198. [PMID: 21531325 DOI: 10.1053/j.ackd.2011.03.001] [Cited by in Crossref: 69] [Cited by in F6Publishing: 53] [Article Influence: 6.3] [Reference Citation Analysis]
13 Wagner B, Drel V, Gorin Y. Pathophysiology of gadolinium-associated systemic fibrosis. Am J Physiol Renal Physiol 2016;311:F1-F11. [PMID: 27147669 DOI: 10.1152/ajprenal.00166.2016] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
14 Ross C, De Rosa N, Marshman G, Astill D. Nephrogenic systemic fibrosis in a gadolinium-naïve patient: Successful treatment with oral sirolimus: Sirolimus and NSF. Australasian Journal of Dermatology 2015;56:e59-62. [DOI: 10.1111/ajd.12176] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
15 Perazella MA. Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm. Curr Opin Nephrol Hypertens 2009;18:519-25. [PMID: 19623065 DOI: 10.1097/MNH.0b013e3283309660] [Cited by in Crossref: 34] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
16 Mayr M, Burkhalter F, Bongartz G. Nephrogenic systemic fibrosis: Clinical spectrum of disease. J Magn Reson Imaging 2009;30:1289-97. [DOI: 10.1002/jmri.21975] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
17 Hazelton JM, Chiu MK, Abujudeh HH. Nephrogenic Systemic Fibrosis: A Review of History, Pathophysiology, and Current Guidelines. Curr Radiol Rep 2019;7. [DOI: 10.1007/s40134-019-0312-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
18 Hasebroock KM, Serkova NJ. Toxicity of MRI and CT contrast agents. Expert Opin Drug Metab Toxicol 2009;5:403-16. [PMID: 19368492 DOI: 10.1517/17425250902873796] [Cited by in Crossref: 140] [Cited by in F6Publishing: 110] [Article Influence: 11.7] [Reference Citation Analysis]
19 Perazella MA, Reilly RF. Imaging patients with kidney disease: how do we approach contrast-related toxicity? Am J Med Sci 2011;341:215-21. [PMID: 21139495 DOI: 10.1097/MAJ.0b013e3181f016e6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
20 Vedvyas C, Winterfield LS, Vleugels RA. Calciphylaxis: a systematic review of existing and emerging therapies. J Am Acad Dermatol 2012;67:e253-60. [PMID: 21821309 DOI: 10.1016/j.jaad.2011.06.009] [Cited by in Crossref: 91] [Cited by in F6Publishing: 63] [Article Influence: 8.3] [Reference Citation Analysis]
21 Kalisiak M, Courtney M, Lin A, Brassard A. Calcific uremic arteriolopathy (calciphylaxis): successful treatment with sodium thiosulfate in spite of elevated serum phosphate. J Cutan Med Surg 2009;13 Suppl 1:S29-34. [PMID: 19480749 DOI: 10.2310/7750.2009.00007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
22 Blaha T, Nigwekar S, Combs S, Kaw U, Krishnappa V, Raina R. Dermatologic manifestations in end stage renal disease. Hemodial Int 2019;23:3-18. [PMID: 30520561 DOI: 10.1111/hdi.12689] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
23 Lemy AA, del Marmol V, Kolivras A, High WA, Matos C, Laporte M, Nortier JL. Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: A single-center experience. Journal of the American Academy of Dermatology 2010;63:389-99. [DOI: 10.1016/j.jaad.2009.10.038] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
24 Panesar M, Yacoub R. What is the role of renal transplantation in a patient with nephrogenic systemic fibrosis? Seminars in Dialysis 2011;24:373-4. [DOI: 10.1111/j.1525-139x.2011.00913.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Daftari Besheli L, Aran S, Shaqdan K, Kay J, Abujudeh H. Current status of nephrogenic systemic fibrosis. Clin Radiol. 2014;69:661-668. [PMID: 24582176 DOI: 10.1016/j.crad.2014.01.003] [Cited by in Crossref: 78] [Cited by in F6Publishing: 56] [Article Influence: 9.8] [Reference Citation Analysis]